CORONA Remedies Q1FY27 Revenue up 21.9% to ₹422.4 Cr, PAT grows 30.1%
CORONA Remedies reported Q1FY27 unaudited results with revenue up 21.9% to ₹422.4 Cr and PAT up 30.1% to ₹60.1 Cr. The company inaugurated its EU-GMP approved Female Hormone Manufacturing Facility on June 30, 2026. CORONA continues to be the fastest-growing company among top 30 IPM companies.
The significant revenue and profit growth, market outperformance, and the commissioning of a new EU-GMP approved facility are material positive developments for the company.
The company reported strong year-on-year growth in revenue and profit, alongside market share gains and the successful launch of a new manufacturing facility.
CORONA Remedies Limited has announced its unaudited financial results for the first quarter of FY27 (Q1FY27), ending June 30, 2026. The company reported a revenue of ₹422.4 crore, marking a significant year-on-year growth of 21.9%, driven by strong brand building and operational excellence.
Profit After Tax (PAT) for the quarter stood at ₹60.1 crore, an increase of 30.1% compared to the same period last year. PAT margins improved by 90 basis points to 14.2%, while EBITDA grew by 33.5% to ₹93.1 crore, with EBITDA margins expanding by 190 basis points to 22.0%.
CORONA continues to outperform the Indian Pharmaceutical Market (IPM), being the fastest-growing company among the top 30 for six consecutive months as per MAT June '26 data. The company has moved up to the 26th rank in the IPM as of MAT June '26, a progression of 3 places in a year. It also holds a 5th rank in the Gynaecology segment.
A key development during the quarter was the inauguration and commercialization of the EU-GMP approved Female Hormone Manufacturing Facility in Ahmedabad on June 30, 2026. Additionally, the company has initiated the smooth integration of the acquired brand 'Wokadine' from both supply and distribution perspectives.
Mr. Nirav K. Mehta, Managing Director & CEO, expressed satisfaction with the performance, highlighting the commitment to consistent growth and operational excellence. He stated that the company aims to focus on core therapies such as Women's Healthcare, Cardio-diabetes, Pain Management, and Urology, while also strengthening its presence in the Infertility and Biosimilar segments.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.